Abstract |
Intramuscular injection of adeno-associated viral (AAV) vector to skeletal muscle of humans with hemophilia B is safe, but higher doses are required to achieve therapeutic factor IX (F.IX) levels. The efficacy of this approach is hampered by the retention of F.IX in muscle extracellular spaces and by the limiting capacity of muscle to synthesize fully active F.IX at high expression rates. To overcome these limitations, we constructed AAV vectors encoding F.IX variants for muscle- or liver-directed expression in hemophilia B mice. Circulating F.IX levels following intramuscular injection of AAV-F.IX-K5A/V10K, a variant with low-affinity to extracellular matrix, were 2-5 fold higher compared with wild-type (WT) F.IX, while the protein-specific activities remained similar. Expression of F.IX-R338A generated a protein with 2- or 6-fold higher specific activity than F.IX-WT following vector delivery to skeletal muscle or liver, respectively. F.IX-WT and variant forms provide effective hemostasis in vivo upon challenge by tail-clipping assay. Importantly, intramuscular injection of AAV-F.IX variants did not trigger antibody formation to F.IX in mice tolerant to F.IX-WT. These studies demonstrate that F.IX variants provide a promising strategy to improve the efficacy for a variety of gene-based therapies for hemophilia B.
|
Authors | Joerg Schuettrumpf, Roland W Herzog, Alexander Schlachterman, Antje Kaufhold, Darrel W Stafford, Valder R Arruda |
Journal | Blood
(Blood)
Vol. 105
Issue 6
Pg. 2316-23
(Mar 15 2005)
ISSN: 0006-4971 [Print] United States |
PMID | 15550487
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adenoviridae
- Amino Acid Substitution
- Animals
- Factor IX
(genetics)
- Genetic Therapy
- Hemophilia B
(genetics, therapy)
- Hemostasis
(genetics)
- Humans
- Liver
(metabolism)
- Mice
- Mice, Knockout
- Muscle, Skeletal
(metabolism)
- Organ Specificity
(genetics)
- Point Mutation
|